GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.
GlycoEra has raised $130.0M in total funding. The most recent round was Series B. The last funding was announced in May 2025.
GlycoEra's investors include Catalio Capital Management, 5AM Ventures, Novo Holdings, Sofinnova Partners, Agent Capital.
GlycoEra is headquartered in Schlieren, Switzerland.
GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.
GlycoEra is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GlycoEra — Funding & Investors." VCBacked, May 27, 2025, https://www.vcbacked.co/company/glycoera. Accessed July 31, 2026.
VCBacked. (2025). GlycoEra — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/glycoera
{{cite web |title=GlycoEra — Funding & Investors |url=https://www.vcbacked.co/company/glycoera |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated